Oregon, WI, United States of America

Leon W LeVan

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Genzyme Corporation. Active years: 2006.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Leon W. LeVan

Introduction

Leon W. LeVan is an accomplished inventor based in Oregon, Wisconsin. He has made significant contributions to the field of pharmaceuticals, particularly in the formulation of lipophilic therapeutic agents. His innovative work has led to the development of a unique patent that addresses the solubilization of these agents in aqueous vehicles.

Latest Patents

Leon W. LeVan holds a patent for a formulation for lipophilic agents. This invention relates to pharmaceutical formulations that enable lipophilic therapeutic agents to be solubilized in largely aqueous vehicles. The processes for preparing and using these formulations are crucial for enhancing the effectiveness of various therapeutic applications.

Career Highlights

LeVan is associated with Genzyme Corporation, where he has been able to apply his expertise in pharmaceutical formulations. His work has contributed to advancements in the delivery of therapeutic agents, making treatments more effective for patients.

Collaborations

Throughout his career, Leon has collaborated with notable colleagues, including Richard B. Mazess and Jeffrey W. Driscoll. These partnerships have fostered an environment of innovation and have led to the successful development of new pharmaceutical solutions.

Conclusion

Leon W. LeVan's contributions to the field of pharmaceuticals through his innovative patent and collaborations highlight his role as a significant inventor. His work continues to impact the effectiveness of therapeutic agents in the medical field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…